World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
58
Citations
12104
World Ranking
3520
National Ranking
1631

Overview

L F Fries is affiliated with Novavax in the United States and has focused their research primarily within the field of Medicine, contributing extensively to several subfields including Infectious Diseases, Epidemiology, Immunology, Public Health, Environmental and Occupational Health, and Radiology, Nuclear Medicine and Imaging.

Their recent research output features papers published mainly between 2020 and 2022, with significant contributions to the understanding of vaccine development and infectious disease control. Notable publications include:

  • Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (2020, New England Journal of Medicine)
  • SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice (2021, Nature Communications)
  • Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial (2021, The Lancet)
  • Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants (2020, New England Journal of Medicine)
  • Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial (2022, The Lancet Infectious Diseases)

L F Fries' work covers significant topics such as SARS-CoV-2 and COVID-19 research, COVID-19 clinical research studies, influenza virus research studies, monoclonal and polyclonal antibodies research, respiratory viral infections research, animal virus infections studies, and malaria research and control.

Throughout their career, Fries has commonly published in venues like bioRxiv (Cold Spring Harbor Laboratory), Journal of Infection, Microorganisms, Open Forum Infectious Diseases, and New England Journal of Medicine, indicating a broad dissemination of research findings across both preprint and peer-reviewed platforms.

Frequent collaborators in their research include Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Iksung Cho, and Gregory M. Glenn. These partnerships reflect contributions to numerous studies and vaccine development efforts with shared expertise.

Best Publications

  • Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.

    Cheryl Keech;Gary Albert;Iksung Cho;Andreana Robertson

  • The role of complement in inflammation and phagocytosis

    Michael M Frank;Louis F Fries

  • Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.

    Vivek Shinde;Sutika Bhikha;Zaheer Hoosain;Moherndran Archary

  • SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.

    Jing Hui Tian;Nita Patel;Robert Haupt;Haixia Zhou

  • Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

    Mehreen S Datoo;Magloire H Natama;Athanase Somé;Ousmane Traoré

  • Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants

    Shabir A Madhi;Fernando P Polack;Pedro A Piedra;Flor M Munoz

  • Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers

    Shelly A. McNeil;Scott A. Halperin;Joanne M. Langley;Bruce Smith

  • Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes.

    C G Pommier;S Inada;L F Fries;T Takahashi

  • Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy

    Louis F. Fries;Daniel M. Gordon;Roberta L. Richards;James E. Egan

  • Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade.

    L F Fries;H M Friedman;G H Cohen;R J Eisenberg

  • Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.

    Milan Basta;Paul Kirshbom;Michael M. Frank;Louis F. Fries

  • A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine

    Louis F. Fries;Gale E. Smith;Gregory M. Glenn

  • Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2.

    Roselyn J. Eisenberg;Manuel Ponce de Leon;Harvey M. Friedman;Louis F. Fries

  • A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age

    Gregory M. Glenn;Louis F. Fries;D. Nigel Thomas;Gale Smith

  • Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine

    Gregory M. Glenn;Gale Smith;Louis Fries;Rama Raghunandan

  • C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I.

    Louis F. Fries;Thelma A. Gaither;Carl H. Hammer;Michael M. Frank

  • Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines

    Ali Fattom;Yun Hee Cho;Chiayung Chu;Steven Fuller

  • Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

    Gale E. Smith;David C. Flyer;Ramadevi Raghunandan;Ye Liu

  • Clinical Manifestations of Plasmodium falciparum Malaria Experimentally Induced by Mosquito Challenge

    L. W. Preston Church;Thong P. Le;Joe P. Bryan;Daniel M. Gordon

  • High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes

    Milan Basta;Louis F. Fries;Michael M. Frank

Frequent Co-Authors

Michael M. Frank
Michael M. Frank Duke University
Gale Smith
Gale Smith Novavax (United States)
Pedro A. Piedra
Pedro A. Piedra Baylor College of Medicine
David W. Vaughn
David W. Vaughn Bill & Melinda Gates Foundation
Mary Lou Clements
Mary Lou Clements Johns Hopkins University
Ruth A. Karron
Ruth A. Karron Johns Hopkins University
Bruce L. Innis
Bruce L. Innis GlaxoSmithKline (United Kingdom)
Brian R. Murphy
Brian R. Murphy National Institute of Allergy and Infectious Diseases
Paul T. Heath
Paul T. Heath St George's, University of London
Matthew B. Frieman
Matthew B. Frieman University of Maryland, Baltimore

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in immunology often intersects with various healthcare paths, including nursing and advanced practice roles. For those interested in expanding their clinical expertise, obtaining an acute care NP certification can open doors to specialized patient care, especially in acute settings.

Many students transitioning into immunology-related healthcare professions benefit from flexible education options. Programs like the accelerated NP programs offer a faster route to becoming a nurse practitioner, blending rigorous academics with practical experience.

For those without a nursing background, exploring online ABSN programs for non nurses provides a tailored pathway to enter nursing while balancing other commitments. These programs are designed to equip students with foundational nursing knowledge efficiently.

Additionally, if you're seeking quicker entry points into nursing, the easiest accelerated nursing programs can be a practical choice. These programs are known for simpler admission processes while maintaining quality education.

Combining immunology study with nursing credentials paves the way for impactful careers in healthcare, research, and patient care, offering diverse opportunities for growth and specialization.

Best Scientists Citing L F Fries

Trending Scientists

Recently Published Articles